Amendment Statement of Principles concerning myeloma No. 73 of 2014

Administered by Department of Veterans' Affairs

Legislation au F2014L00935 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 73 OF 2014

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority) has determined, under subsection 196B(10) of the Veterans’ Entitlements Act 1986 (the VEA) Amendment Statement of Principles Instrument No. 73 of 2014 concerning myeloma.
  2. This instrument amends Statement of Principles Instrument No. 70 of 2012 concerning myeloma by:
  • inserting new factor 6(ca) concerning 'exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD)'; and
  • specifying the date of effect of this amendment.

3.             The changes are made at the direction of the Specialist Medical Review Council (the SMRC) in accordance with its Declaration No. 23 dated 12 May 2014.  The SMRC Declaration appeared in the Government Notices Gazette of 13 May 2014.

4.             In accordance with subsection 196B(13) of the VEA, the changes as made by Instrument No. 73 of 2014, take effect from 13 May 2014.

5.             As these changes provide additional means by which myeloma can be related to relevant service the earlier date of effect does not affect the rights of claimants so as to disadvantage them nor would it impose additional liabilities on them.

6.             No consultation was undertaken by the Authority prior to determining this Instrument, as the changes are made at the direction of the SMRC in accordance with section 196W of the VEA. The SMRC undertook public notification and consultation as part of its consideration of the matter, inviting eligible persons or organisations to make submissions. The SMRC decision, and directions to the Authority, were contained in a Declaration published in the Government Notices Gazette of 13 May 2014.

7.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Amendment Statement of Principles No. 73 of 2014

Kind of Injury, Disease or Death: Myeloma

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(10) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have myeloma;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • includes a new factor which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, myeloma is connected with the circumstances of eligible service rendered by a person;
  • amends Instrument No. 70 of 2012; and
  • reflects the Specialist Medical Review Council's review of the available sound medical-scientific evidence concerning myeloma considered by the Repatriation Medical Authority when that earlier instrument was determined.

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

[1] In General Comment No. BP (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 73 of 2014 is a legislative instrument amending the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA) concerning myeloma. Enacted to address the need for a more precise understanding of the connection between myeloma and military service, particularly in relation to exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD), this instrument was determined under the authority of the Repatriation Medical Authority and in accordance with the directives of the Specialist Medical Review Council (SMRC). The policy objective is to facilitate the assessment and determination of claims related to myeloma, ensuring that claimants can access the appropriate medical treatment and compensation, and to uphold the human rights of veterans and their dependents, including their rights to social security and health. This legislative instrument aims to improve the medico-scientific quality of outcomes by specifying new factors necessary for establishing a connection between myeloma and military service, thereby reflecting the most current sound medical-scientific evidence.

Scope and Application

The Repatriation Medical Authority Instrument No. 73 of 2014, which amends the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, applies to eligible persons who have been diagnosed with myeloma and are seeking medical treatment or compensation related to their service. The Instrument specifies the circumstances under which these individuals can receive compensation, facilitating both the claim process and the assessment of such claims by the Repatriation Commission and Military Rehabilitation and Compensation Commission. This legislative instrument introduces a new factor concerning exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD), enhancing the criteria for connecting myeloma with relevant service. The changes were determined by the Specialist Medical Review Council, which directed the Authority to make these amendments in line with its Declaration No. 23 dated 12 May 2014. The instrument is effective from 13 May 2014 and ensures that the rights of claimants are not disadvantaged by the earlier date of effect. It is a technical instrument that improves the medico-scientific quality of outcomes under the VEA and the MRCA and is compatible with human rights as it promotes the rights of veterans, current and former Defence Force members, and their dependents.

Key Provisions

The Repatriation Medical Authority Instrument No. 73 of 2014 amends the Statement of Principles Instrument No. 70 of 2012 concerning myeloma, by inserting a new factor (6(ca)) relating to exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD) (section 3). The instrument takes effect from 13 May 2014, as per subsection 196B(13) of the Veterans’ Entitlements Act 1986 (VEA) (section 4). This amendment is made under the direction of the Specialist Medical Review Council (SMRC) in accordance with section 196W of the VEA (section 3). The instrument facilitates the process of making, assessing, and reviewing claims for medical treatment and compensation for veterans, current and former Defence Force members, and their dependents who have been diagnosed with myeloma (section 2). The instrument imposes certain obligations on the Repatriation Commission and Military Rehabilitation and Compensation Commission to consider the new factor when assessing claims, and it facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal (section 2). Claimants must provide evidence of exposure to TCDD in addition to the existing factors to substantiate their claim. The SMRC's review and the resulting amendment reflect the latest sound medical-scientific evidence and aim to improve the medico-scientific quality of outcomes under the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA) (section 2 and 3). The Legislative Instrument outlines specific offences and penalties for breaches, though it does not detail these in the explanatory notes. Typically, under the VEA and the MRCA, penalties for false claims or fraudulent activities could include fines and imprisonment, as well as the potential for recovery of benefits paid. The maximum penalties for such offences can vary, but they are significant enough to deter fraudulent activities. The instrument also ensures that the rights of claimants are not adversely affected and that no additional liabilities are imposed on them due to the earlier date of effect (section 5). This instrument is compatible with human rights as it promotes several rights, including the right to social security, an adequate standard of living, and the highest attainable standard of physical and mental health (section 4). It does not derogate from any human rights and ensures that the qualifying conditions for benefits are reasonable, proportionate, and transparent (section 4). The instrument thus supports the rights of veterans and Defence Force members, including those with disabilities, by facilitating the assessment and determination of claims related to treatment and rehabilitation (section 4).

Legal classification tags

Area of Law
Veterans' Law
Instrument
Regulation
Concepts
Definitions & Interpretation
Reporting & Disclosure Obligations
Human Rights Law

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.